Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA chooses IBM, KMPG, Merck and Walmart for pharma blockchain pilot
  2. Lonafarnib, a hope for progeria treatment
  3. How simplification and behaviour change can optimise a pharmaceutical operation
  4. The top selling prescription drugs by revenue
  5. Charity LifeArc sells rights to Keytruda for more than $1bn

Latest Content

Lonafarnib, a hope for progeria treatment

Lonafarnib has emerged as a potential treatment for progeria and progeroid laminopathies, an ultra-rare condition for which no approved treatment exists.
Having successfully demonstrated survival benefits in progeria patients, lonafarnib is improving the hope for the patients, who generally succumb to death at an early age of 14 years.
The drug currently has orphan drug, breakthrough therapy, as well as rare paediatric disease (RPD) designations from the US Food and Drug Administration (FDA).

ILC Dover manufacturing facility

ILC Dover Manufacturing Facility

In May 2019, ILC Dover opened a manufacturing facility in Ireland to produce the company’s pharmaceutical and biopharmaceutical product lines. The plant is designed to strengthen the company's single-use powder handling solutions business.

May’s top news stories

Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn, and The UK’s NHS has signed a managed access agreement to fund Biogen’s Spinraza for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA). Pharmaceutical-technology.com wraps up key headlines from May 2019.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top